-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
DURHAM, N.
The research was published online April 20 in the journal Frontiers in Cell and Developmental Biology
When COVID-19 began spreading globally in early 2020, doctors knew that the virus primarily infects cells of the respiratory tract
The issue caught the attention of Samira Musah, who participated in a virtual workshop in the spring of 2020
“It was shocking to hear doctors describe healthy patients who suddenly developed kidney damage after contracting SARS-CoV-2 and required dialysis,” Musah said.
In previous work, Musah and her team showed they could guide human induced pluripotent stem cells to develop and mature into functional podocytes, a specialized type of kidney cell that helps control toxins and waste in the blood of clearing
As a proof of concept, Kalejaiye initially worked with a pseudovirus version of SARS-CoV-2
"We found that the virus is particularly good at binding to two key receptors on the surface of podocytes, which are abundant in these kidney cells," explained Kalejaiye, who is also the paper's first author
To test their podocyte model with the real SARS-CoV-2 virus, Musah and Kalejaiye collaborated with Maria Blasi, an assistant professor of medicine at Duke University and a researcher at the Duke Human Vaccine Institute
Like the pseudovirus, the team found that the live virus has a strong affinity for podocytes
"In addition to the structural damage, we found that the virus can hijack the podocyte's machinery to produce additional viral particles that can spread to other cells," Blasi said
Now, the team hopes to expand their work to study how different variants of SARS-CoV-2 behave in kidney cells
"I think it's pretty remarkable that we went from staying home and hearing the initial reports from doctors, to having a partnership online and getting these results in such a short period of time," Musah said
SARS-CoV-2 Employ BSG/CD147 and ACE2 Receptors to Directly Infect Human Induced Pluripotent Stem Q2 Cell-Derived Kidney Podocytes